Clinical Trial Design: Statistical Options/Challenges Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Opening Session Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Mar

Today In Oncology

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Related Videos

Opening Session Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Awareness of Alcohol-Cancer Link Holds Steady Despite Omission in New US Dietary Guidelines

Myelofibrosis Treatment Landscape Is Poised for Change

AI Model Classifies Challenging Thymic Epithelial Tumors

Study Finds Inferior Survival Among Black Patients With AML, Independent of Cytogenetic Risk

Lisocabtagene Maraleucel in Relapsed or Refractory MZL